Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Net Income towards Common Stockholders: 2016-2025

Historic Net Income towards Common Stockholders for Akebia Therapeutics (AKBA) over the last 9 years, with Sep 2025 value amounting to $540,000.

  • Akebia Therapeutics' Net Income towards Common Stockholders rose 102.69% to $540,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.9 million, marking a year-over-year increase of 65.42%. This contributed to the annual value of -$69.4 million for FY2024, which is 33.67% down from last year.
  • Per Akebia Therapeutics' latest filing, its Net Income towards Common Stockholders stood at $540,000 for Q3 2025, which was up 118.62% from $247,000 recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Net Income towards Common Stockholders registered a high of $29.4 million during Q2 2022, and its lowest value of -$70.4 million during Q4 2021.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$11.2 million (2023), whereas its average is -$10.4 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first skyrocketed by 142.32% in 2022, then slumped by 3,814.01% in 2024.
  • Quarterly analysis of 5 years shows Akebia Therapeutics' Net Income towards Common Stockholders stood at -$70.4 million in 2021, then spiked by 90.76% to -$6.5 million in 2022, then skyrocketed by 109.44% to $614,000 in 2023, then plummeted by 3,814.01% to -$22.8 million in 2024, then soared by 102.69% to $540,000 in 2025.
  • Its Net Income towards Common Stockholders was $540,000 in Q3 2025, compared to $247,000 in Q2 2025 and $6.1 million in Q1 2025.